- Home
- ADXN vs ICCM Comparison
ADXN vs ICCM Comparison
Compare ADXN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADXN | ICCM |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 8.3M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ADXN | ICCM |
|---|---|---|
| Price | $3.12 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 13.9K | ★ 162.7K |
| Earning Date | 09-28-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $767.75 | $34.08 |
| Revenue Next Year | N/A | $94.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $0.13 |
| 52 Week High | $11.97 | $9.54 |
Technical Indicators
Market Signals| Indicator | ADXN | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 16.69 |
| Support Level | $3.10 | $0.22 |
| Resistance Level | $3.80 | $2.50 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 50.00 | 3.95 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.